Respiration monitoring is important for evaluating human health. Humidity sensing is a promising way to establish a relationship between human respiration and electrical signal. This work describes polymer humidity sensors with ultrafast response for respiration monitoring. The humidity-sensitive polyelectrolyte is in situ cross-linked on the substrate printed with interdigitated electrodes by a thiol–ene click reaction. The polyelectrolyte humidity sensor shows rapid water adsorption/desorption ability, excellent stability, and repeatability. The sensor with ultrafast response and recovery (0.29/0.47 s) when changing humidity between 33 and 95% shows good application prospects in breath monitoring and touchless sensing. Different respiration patterns can be distinguished, and the breath rate/depth of detection subjects can also be determined by the sensor. In addition, the obtained sensor can sense the skin evaporation in a noncontact way.

No abstract

Motivation Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70 000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. Results Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency and patient burden. We recently developed a computational protocol named as SCAR (steric-clashes alleviating receptors) for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least six hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19. Contact senliu.ctgu@gmail.com